Skip to main content

A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Start Date

February 14, 2023

End Date

February 28, 2028
 

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Start Date

February 14, 2023

End Date

February 28, 2028